DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 12:11:36 2024-07-03 EDT | ||
| 71.21 EUR / 71.24 EUR | -0.75% |
|
| Current month | -0.06% | ||
| 1 month | +1.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 71.47 | -0.40% |
| 24-07-02 | 71.76 | -0.13% |
| 24-07-01 | 71.85 | +0.07% |
| 24-06-28 | 71.8 | -0.14% |
| 24-06-27 | 71.9 | -0.21% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 06:36 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1C9R |
| ISIN | DE000MG1C9R8 |
| Date issued | 2024-04-02 |
| Maturity | 2025-03-21 (261 Days) |
| Parity | 1 : 1 |
| Emission price | 70.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 72.05 € |
|---|---|
| Lowest since issue | 68.94 € |
| Spread | 0.02 € |
| Spread % | 0.03% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
